Analyst Reco. Kymera Therapeutics, Inc.

Stocks

KYMR

US5015751044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/06/2026 BST			5-day change	1st Jan Change
78.23 ^USD	+1.72%		+6.86%	+0.54%

06-09	Kymera Therapeutics Unlocks $20 Million Milestone After Dosing First Participant in KT-485 Phase 1 Trial	MT
06-08	Kymera Therapeutics, Inc. Announces Executive Changes	CI

Analyst Reco.

05-06	Canaccord Genuity Initiates Kymera Therapeutics at Buy With $106 Price Target	MT
03-03	UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating	MT
12-22	B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating	MT
12-16	Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says	MT
12-16	RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk	MT
12-11	Mizuho Raises Price Target on Kymera Therapeutics to $120 From $81, Keeps Outperform Rating	MT
12-09	Oppenheimer Adjusts Kymera Therapeutics PT to $120 From $67, Maintains Outperform Rating	MT
12-09	Truist Securities Adjusts Kymera Therapeutics PT to $116 From $80, Maintains Buy Rating	MT
12-09	Morgan Stanley Raises Price Target on Kymera Therapeutics to $127 From $73, Keeps Overweight Rating	MT
11-25	Truist Securities Raises Price Target on Kymera Therapeutics to $80 From $68, Maintains Buy Rating	MT
24/10/25	B. Riley Boosts Price Target on Kymera Therapeutics to $80 From $60, Keeps Buy Rating	MT
21/10/25	Mizuho Initiates Kymera Therapeutics at Outperform With $81 Price Target	MT
30/09/25	Truist Raises Price Target on Kymera Therapeutics to $68 From $53, Keeps Buy Rating	MT
17/09/25	Barclays Initiates Kymera Therapeutics at Overweight With $60 Price Target	MT
16/09/25	RBC Initiates Kymera Therapeutics at Outperform, Speculative Risk With $70 Price Target	MT
27/06/25	Oppenheimer Adjusts Kymera Therapeutics Price Target to $53 From $56, Maintains Outperform Rating	MT
26/06/25	HC Wainwright Adjusts Price Target on Kymera Therapeutics to $60 From $54, Maintains Buy Rating	MT
03/06/25	Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says	MT
03/06/25	Stifel Adjusts Price Target on Kymera Therapeutics to $68 From $55, Maintains Buy Rating	MT
03/06/25	B. Riley Upgrades Kymera Therapeutics to Buy From Neutral, Adjusts Price Target to $60 From $38	MT
03/06/25	Morgan Stanley Upgrades Kymera Therapeutics to Overweight From Equalweight, Raises Price Target to $79 From $49	MT
02/06/25	BofA Securities Upgrades Kymera Therapeutics to Buy From Neutral, $51 Price Target; Shares Rise	MT
13/05/25	UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating	MT
12/05/25	B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating	MT
13/03/25	Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target	MT